BioVie is eyeing a $19.7 million IPO for a spinout focused on bringing a new formulation of an approved kidney failure drug to market as a potential treatment for liver disease. | BioVie is eyeing a ...
Salspera has set out plans for a $91 million IPO to fund the phase 3 study of its bacteria-based cancer therapy. | Salspera has set out plans for a $91 million IPO to fund the phase 3 study of its ...
More than 10 pre-profit drug developers are seeking Hong Kong listings as AI-powered biotech platforms draw growing investor interest More than 10 loss-making biotechnology companies have filed for ...
For all of the benefit that radiopharmaceuticals offer, these treatments currently address a limited number of cancer targets. Aktis Oncology has technology that could broaden the reach of this type ...
Biotech IPOs fell to a decade low in 2025 Investors expect more listings amid easing rate pressure Policy clarity under Trump has reduced worst-case fears Late-stage drug pipelines drawing renewed ...
Chungui International BioTech Group has filed for an initial public offering. The consumer goods company said it will sell 3 million units at $5 apiece, according to a filing with the Securities and ...
The biotech industry’s challenging years might finally be giving way to more optimism as a new funding wave takes shape.
The companies Vaxcyte, Generate Biomedicines, and Immunic bagged the biggest biotech funding rounds overall in February 2026.
MapLight Therapeutics Inc.’s (NASDAQ: MPLT) initial public offering tempted some huge insider buying. Kinder Morgan Inc. (NYSE: KMI), MSC Industrial Direct Co. Inc. (NYSE: MSM), and others also saw ...
The life sciences industry is poised for an upswing in initial public offering (IPO) activity in 2026, supported by a large IPO backlog, the strong performance of biotech market indices, and positive ...
Hosted on MSN
There's a biotech boom in dealmaking
Biotech is dominating the (very) early 2026 deals market, whether that be startup fundings, IPOs, or mergers. Why it matters: This is a reversal of the usual order, in which biotech plays distant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results